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ABSTRACT 
 
Bone grafts are commonly used for the treatment of large bone defects. 
Biodegradable, synthetic bone grafts combined with cells and growth factors as a tissue 
engineered construct can provide benefits over the common autografts and allografts 
currently used. Calcium phosphate (CaP) materials offer high biocompatibility and 
chemical similarity to natural bone tissue. Biodegradable beta-tricalcium phosphate (β-
TCP) scaffolds with an interconnected porous network have been created to promote 
tissue ingrowth and regeneration in vitro and in vivo. Extracellular matrix (ECM) coated 
on titanium and polymer scaffolds has been shown to improve cell response to those 
material surfaces. Here, we attempted to further improve the biocompatibility of the 
interconnected β-TCP ceramic scaffolds by generating a cell derived ECM on the ceramic 
surface in vitro. Cell derived ECM was generated on scaffolds for 1, 7, 14, 21, or 28 days 
of culture. Scaffolds were decellularized and sterilized to isolate the ECM coating on the 
β-TCP scaffolds. Osteogenic medium-soaked scaffolds treated for the same time periods 
as ECM coated scaffolds and autoclaved, untreated scaffolds were used as controls. The 
behavior of preosteoblasts seeded onto each scaffold was examined over a 28 day period. 
Cellular assays for cell number, alkaline phosphatase (ALP), and total protein (TP) were 
measured. Cell morphology changes on the scaffold were observed by scanning electron 
microscopy. The cell count on all scaffolds reached a plateau after 14 days. Specific ALP 
and specific TP slowly increased during the 28 days for all groups. New ECM was visible 
after 14 days of generation time on all groups. No significant difference was seen 
between the untreated scaffold control, the 1, 7, 14, 21, or 28 day ECM-coated scaffolds, 
or the 1, 7, 14, 21, or 28 day medium-soaked scaffolds (eleven groups). This study 
verifies the high biocompatibility of β-TCP scaffolds and suggests that a cell derived 
biological coating on the β-TCP scaffolds offers no significant changes to the attachment 
rates or differentiation rate of seeded cells. Future studies will seek to find other benefits 
of the ECM coating, like use as a bioactive agent delivery vehicle. 
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CHAPTER 1. INTRODUCTION 
Bone graft surgeries are performed to enhance the healing of fractures and defects 
caused by trauma or disease. An estimated 7.9 million fractures occur in the United States 
annually, with approximately 1.5 million bone graft operations performed to treat those 
injuries.1 Most large bone defects will not heal without the aid of bone grafts. Commonly 
an autograft treatment is performed to fill a bone void, using tissue from the patient’s own 
body. Unfortunately the tissue harvest requires a second surgery, and only a limited 
amount of bone may be collected from the patient. If there is a need for large volumes of 
bone tissue, an allograft from a donor, usually a cadaver, may provide it. However, this 
donated tissue could potentially elicit an immune response or deliver diseased bone.2 
These complications show that despite the widespread use of these operations, neither is 
ideal. Tissue engineering seeks to develop a synthetic alternative at least as effective in 
bony healing. Such a material would not be limited by supply and be completely 
biocompatible, degrade safely after implantation and healing, and provide a stable 
scaffolding on which bone tissue could thrive.  
The design of synthetic materials is inspired by the tissue it seeks to replace. 
Polymers, metals, and ceramics can each be manipulated to mimic some aspect of bone. 
The strength of bone, however, stems from its composite nature. The hard tissue can be 
approximated by a ceramic material, while the extracellular matrix (ECM) that permeates 
it acts like a reinforcing polymer. The two materials give bone its high mechanical 
strength and resistance to shear forces. At the porous center of long bones, the marrow 
produces stem cells for use by the entire body. Mimicking the composite and porous 
nature of bone has become a great challenge for tissue engineers, and one we hope to 
overcome with our unique ceramic scaffolds.  
Our lab has focused on fabricating calcium phosphate (CaP) ceramics for 
treatment of bone void defects. Using beta-tricalcium phosphate (β-TCP) synthesized into 
a porous, biomimetic disc provides a biodegradable scaffold that can be integrated with 
developing bone tissue. In an attempt to mimic the composite nature of bone, a cell-
deposited ECM will be laid on the scaffolds prior to use. Using the ECM as a way to 
enhance material interaction with developing cells has been performed in vitro by Datta 
et al. who saw increased cell number and calcium deposition when titanium mesh 
constructs were coated with ECM.3 The use of various polymers as a means of bioactive 
agent delivery has also been explored.4 However, using a natural polymer like ECM with 
a synthetic CaP scaffold to create a composite material has not been well characterized. 
There is a need to determine the amount of time required for a meaningful amount of 
ECM to be deposited on a ceramic surface and determine the effects such a coating has 
on cell behavior.  
This project sought to determine what behavioral changes occurred for 
preosteoblast cells cultured on ECM-coated CaP scaffolds. An optimal cell culture time 
for ECM deposition on our unique porous CaP scaffolds was also investigated. 
Background information on the tissue engineering concepts necessary for understanding 
the project will be explained. Then the characteristics of the calcium phosphate scaffolds 
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will be examined. The characterization of the ECM deposition process will be explored, 
followed by characterization of cell behavior in response to ECM coated scaffolds. 
Finally, the significance of the results and future directions will be discussed.  
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CHAPTER 2. BACKGROUND 
Bone Tissue 
Bone is a complex and robust tissue that provides a source of primary cells and 
structural support for the entire body. It is a composite material with a rigid, mineralized 
portion integrated with an elastic phase of extracellular matrix throughout. The hard 
“bony” areas provide structure, anchors for articulation of muscles, and physical 
protection of internal organs. The elastic portion gives long bones torsional resistance and 
shock absorbing qualities. Within the bones, the marrow produces stem cells for 
development of blood and lymphocyte cells. Bones are highly vascularized, allowing the 
stem cells to easily distribute throughout the body via the circulatory system.5 The variety 
of functions bone tissue can perform ranges widely, but all the roles are important. 
Characterization of the mechanical properties of bone is not straightforward due 
to their various and often irregular shapes. For most purposes discussed in this paper, 
long bones will be examined. The long bones in a human have very high compressive 
strength for their weight, though this is only along their longitudinal axis. If long bones 
are tested laterally, they do not exhibit such high compressive strength. This unevenness 
is due to the unique arrangement of osteocytes along the axis of load. Cellular feedback 
due to mechanical stress causes osteocytes to align themselves and strengthen in a 
particular direction. This phenomenon is readily demonstrated by astronauts who lose 
bone mass in low gravity environments, where very little mechanical stress is applied to 
the osteocytes.6 
The compressive forces mentioned previously have been estimated to be between 
137 MPa to 206 MPa in human long bones.7 The forces are approaching that of 
aluminum or mild steel, as pointed out by Barrère et al., though bone is much lighter than 
either of these metals. The Young's modulus of bone, a measure of the elasticity of a 
material, is estimated to be 41 MPa to 69 MPa, much less than the metals previously 
mentioned.7 Such high elasticity allows bone to function as a shock absorber when 
impacted.  
Possessing high strength and shock absorbing qualities makes bone a much more 
interesting and multifunctional material than metals. The efficiency of bone can be 
attributed to its composite nature. The inorganic, ceramic-like material infused with an 
elastic polymer of non-mineralized extracellular matrix allows such a lightweight and 
robust tissue to exist.  
Bone regeneration 
In response to trauma or disease, a bone void will undergo a cascade of events to 
protect and then heal the tissue. First a protective layer of fibrous tissue forms around the 
injury site. Fibrous tissue grows more quickly than bone tissue can, and it fills the injury 
space quickly, within days.8 The temporary tissue that covers the wound protects the area 
from infection. The fibrous tissue also provides some stability while the surrounding 
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bone tissue gradually infiltrates and replaces the damaged tissue.  
The surrounding bone tissue of a wound site continues to produce maturing 
osteoblasts and osteoclasts, two opposing cells that constantly remodel the bone. While 
osteoblasts produce mineralized bone and later convert to stable osteocytes, the 
osteoclasts dissolve mineralized tissue.9 Osteoclasts are derived from monocytic 
macrophages, and thus act similarly to phagocytic B-cells. The balance of both cells' 
function keeps bone strong and capable of adjusting to many incidents of trauma. 
Numerous proteins and signaling factors are also secreted locally to direct bone 
healing. In normal bone growth, proteins like alkaline phosphatase, osteocalcin, and 
osteopontin are secreted and used by maturing osteoblasts.10 Growth factors like bone 
morphogenetic protein 2 (BMP-2), which plays a role in osteoblast differentiation, can 
also be found. These same proteins are present in the wound healing environment, and 
there are numerous studies that exploit their growth functions.4 Being able to control the 
delivery of several key bioactive factors could greatly enhance bone regeneration. Due to 
the relatively short half-life of these local factors, methods of drug delivery become very 
important.  
Bone tissue is constantly undergoing remodeling, and even in cases of fracture the 
same basic process continues. Knowledge of the local signaling and environmental 
factors that affect osteoblast development is key to enhancing the regeneration process. 
Critical sized defects 
There are some bone voids that cannot heal due to the large distance between 
areas of intact bone tissue. If the cells cannot bridge the gap to heal naturally over any 
period of time, it is referred to as a critical sized defect.  
A common example of a critical sized defect in humans can be seen in children 
with cleft palates. The missing bone will not heal on its own without surgical 
intervention, so a bone graft surgery is necessary to restore the normal palate structure. In 
research, the rat cranial defects model is commonly used to examine bone healing 
efficacy of a material. Specifically for rat craniums, bone voids larger than 8 mm in 
diameter are considered critically sized. The top of the skull is the only non-load bearing 
area of bone, making it a good model for early in vivo studies of a new biomaterial.  
Indicators of development and mineralization 
Developing osteoblasts produce a number of detectable signaling proteins that can 
be used to determine their maturity. But before this can be measured, certain criteria must 
be met. For example, osteoprogenitor cells will only differentiate into mature, secretory 
osteoblasts if they have reached confluence, or growth arrest, and have an established 
extracellular matrix (ECM).11 The day the proliferative phase has passed is an important 
milestone used as a reference point for further cell behavior. 
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A common early stage marker of osteoblast activity is alkaline phosphatase 
(ALP). After the proliferation period of preosteoblasts has finished (i.e. the cells have 
reached confluence), a measurable increase in ALP production occurs. The ALP levels 
rise for approximately 10 days following the post-proliferative phase, and the time it 
peaks is an indication of cell differentiation into the osteoblast phenotype.12 Alkaline 
phosphatase is an intracellular protein, and while not unique to bone tissue, it is 
nonetheless convenient to test in vitro due to the ease of performing its calorimeteric 
assay with cell lysate.  
Later stages of maturity can be indicated by proteins like osteocalcin (OC) or 
osteopontin (OP), both of which are expressed post-proliferatively and likely linked to 
osteoclast resorption.12  
The final stages of osteoblast maturation depend on reorganization of the 
extracellular matrix, which occurs between 12 and 18 days after proliferation has ceased. 
The remodeling of the ECM fibers also involves upregulation of genes necessary for 
matrix mineralization. When the ECM is rich with growth factors from the transforming 
growth factor beta (TGF-β) superfamily and other proteins, bone mineralization 
commences. At approximately 16 to 20 days post-proliferation, the ECM mineralizes and 
mature bone is formed.12  
Tissue Engineering Concepts 
Tissue engineering requires many biological concepts to be understood when 
designing a material. Several concepts that are important to the success of a composite 
ceramic and polymer biomaterial are described below. 
Biocompatible 
A material is considered biocompatible if a tissue's cells are capable of attaching, 
proliferating, and differentiating on its surface. There is an important distinction between 
this integration of tissue and material compared to inert materials. Even if a surface elicits 
no inflammation or wound response, it may not be considered biocompatible. If a 
material becomes encapsulated in fibrous tissue, this may indicate an inert reaction but 
still an undesirable foreign body response. A biocompatible material has cellular 
attachment directly to its surface without any fibrous tissue encapsulation.  
Biodegradable 
If a material is biodegradable, it can safely be left in vivo until it has completely 
dissolved. While this term does not suggest any particular time frame when a material 
must break down, it is generally assumed that a biodegradable material will show 
significant signs of degradation coincident with the time it takes the tissue to heal. In 
bone repair, this is particularly important in order to reduce the total number of surgeries. 
Ideally, one operation could be performed to implant the biomaterial. Then, the tissue 
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could heal through the degrading material, leaving only naturally developed tissue in its 
place.  
Osteoinductive versus osteoconductive 
An important part of the bone healing process is rebuilding bony tissue in areas 
where it no longer exists. In most cases this void is surrounded by intact bone. If a 
biocompatible material implanted in this void will support bone tissue growth through 
itself, it is called osteoconductive. If the same material is implanted at a site not in contact 
with bone, for example subcutaneously, it may not promote bone tissue formation. A 
material that does cause bone tissue growth in a location where none would have 
naturally occurred is called an osteoinductive biomaterial.  
The tissue harvested for autografts and allografts is osteoinductive.13 Most 
synthetic materials are only osteoconductive. While the goal of synthetic biomaterials is 
intended to repair bone in areas already surrounded by existing tissue, osteoinductive 
materials do provide a stronger healing response after implantation. This response likely 
results from the presence of some growth factors, like bone morphogenetic protein 2 
(BMP-2), that are absent on osteoconductive materials.14 Most synthetic calcium 
phosphate materials are considered osteoconductive.15-17  
Calcium Phosphate Ceramics 
The use of ceramics in bone tissue engineering dates back 40 years when Hulbert 
et al. suggested their use as permanent implants.18 The inorganic phase of bone mineral 
can be described as an impure calcium phosphate apatitic structure laced with carbonate 
groups and other trace elements.19 Synthetic substitutes of inorganic bone are derived 
from calcium orthophosphate salts, which constitute a wide variety of inorganic 
compositions and physicochemical properties.7 These calcium phosphate (CaP) based 
ceramics are used as coatings on metal prostheses, cements in non-load bearing 
applications, and in sintered forms as porous structures.20-22 Currently, the most 
commonly used bone substitute materials are hydroxyapatite (HA) and beta-tricalcium 
phosphate (β-TCP), though these stoichiometrically pure forms lack the trace elements 
and non-apatitic functional groups that distinguish natural bone.19,23 Nevertheless, more 
than half the weight of bone is composed of an HA phase, and this similarity contributes 
to the strong biocompatibility these synthetic materials exhibit in developing tissue.24  
Though both HA and β-TCP are biodegradable, β-TCP breaks down to its 
constituent calcium and phosphate ions more readily in circulating body fluid than HA.25 
In choosing an appropriate ceramic composition for making our porous scaffolds, the 
solubility of β-TCP most closely matched our design goals. The dissolution of the 
calcium phosphate in vitro is dictated by the solution (pH, local calcium or phosphate 
concentration, temperature) and the material properties (crystal organization, surface 
area, density).7 When β-TCP is implanted in vivo, the ceramic degradation can be affected 
by other factors like serum proteins, enzymes, and osteoclast activity. The structure of β-
TCP is similar enough to bone tissue that osteoclasts can also resorb the synthetic 
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material. Osteoclasts resorb bone tissue and β-TCP by secreting hydrochloric acid to 
lower the local pH, thus causing the calcium phosphate to dissolve.26  
Ideally, the synthetic material is solubilized and resorbed by osteoclasts at a rate 
equivalent to the mineralization of new bone. If this occurs, new tissue formation is not 
impeded by the presence of the scaffold, and the ionic components released from the CaP 
structure may be utilized by the developing tissue.27 Successfully orchestrating the 
dissolution of a biomaterial and the growth of natural tissue in its place will be difficult, 
but the use of biocompatible and biodegradable components makes it a possibility.  
Pore size 
When a tissue graft is first exposed to cells, the integration between host tissue 
and foreign material surface largely determines the success of the implant. Despite the 
high biocompatibility of CaP materials, merely providing a biomimetic surface is not 
enough for full bone tissue integration. The architecture of the implant is critical to the 
long-term viability of a bone graft. In creating a synthetic analogue of bone, this means 
mimicking the porosity of cancellous bone.  
The composite nature of bone can describe aspects besides its material 
composition. Spatially, the inorganic phase has two distinct areas, a dense cortical 
exterior layer for structural support and protection, and the interior porous cancellous 
matrix that houses the marrow and extensive vascularization. Many studies have explored 
the best architecture for bone ingrowth, but an interconnected porous network seems 
necessary for full tissue restoration.28-31 Pores allow not only osteoblast cell migration but 
also endothelial cell penetration, so that vascularization can occur. Blood vessel supply is 
vital to any developing cells, so the pores must permit growth of vessels and the 
developing bone tissue.  
Though an ideal pore size is difficult to identify, several groups have found 
approximate benchmark sizes that permit bone tissue growth. For interconnected 
networks, the limiting factor is the size of the interconnections and not the pores 
themselves. Bone graft materials with pore interconnection diameters smaller than 100 
µm only support fibrous tissue ingrowth.18 Interconnections larger than 100 µm allow for 
osteoblast mineralization to occur, but the interconnections must be at least 300 µm for 
vascularization to complement the osteocyte development. So, for osteoid development in 
humans, an acceptable pore interconnection diameter for cell growth and vascularization 
is at least 300 μm.32 The CaP ceramics used in this study have a pore size of 
approximately 500 to 750 μm and pore interconnection size of at least 350 µm. Our 
scaffold fabrication method allows the pore size and pore interconnection size to be 
controlled, and our recent experiments have settled on this architecture to provide a 
balance of mechanical strength and cell viability.  
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Uses in tissue engineering 
Ceramics are currently in use clinically for treating large bone defects. Bone 
cements and ceramic implants have been used successfully in dental and orthopedic 
applications for patients.33,2 The use of HA as a coating for other materials and implants 
speaks to the biocompatibility and resilience of these ceramics.34 Most recently, porous 
and functionally graded ceramic structures are being examined as biomimetic 
replacements for auto and allografts.35  
Extracellular Matrix 
The extracellular matrix (ECM) is a structural network secreted and maintained 
by fibroblast-like cells. It is a complex amalgamation of fibers and bioactive proteins, and 
its role changes drastically depending on the source of its development and its location.36 
In bone, the ECM is responsible for maintaining a stable network for osteoblast precursor 
cells to attach, proliferate, and differentiate on, then the ECM is modified to prepare for 
mineralization.11 Calcium, phosphate, carbonate, and other minerals are deposited on the 
ECM by mature osteoblasts to create the apatite-like phase of bone. It is characterized by 
a polymer-like behavior due to the large weight percentage of collagen fibers that give it 
structure.36  
Proteins of bone extracellular matrix 
In all instances of bone ECM, collagen type I is the most abundant protein. 
Collagen fibers provide a network for cells to attach and use for migration, and they give 
ECM its polymer-like properties. Collagen type I is a structural protein that polymerizes 
into a triple helix of collagen bands, held tightly to one another by hydrogen bonds.37 
Their defining glycine-X-Y amino acid sequence (where X and Y are other amino acids, 
usually proline or hydroproline) also makes the fibers easy to identify and forms a rigid, 
rod-like structure. The repeating sequence also allows the fibers to form into a triple helix 
that provides strength to the collagen type I structure. Beyond just a structural network, 
the ECM maintains the activity of other bioactive proteins and serves as a means of 
communication for attached cells.38 
Cells bind to collagen fibrils or other ECM proteins via transmembrane proteins, 
the integrins. The actin filaments inside of cells indirectly attach to the collagen network 
through these integrin anchors. It is the integrins which simultaneously provide a method 
of motility for the cells on the ECM and a direct line of communication between cells and 
the ECM.39,40  
Proteins like laminin and fibronectin, which function as adhesion molecules, can 
be found in the all types of ECM.41,42 Other proteins like bone sialoprotein, involved in 
ECM mineralization, and osteocalcin, involved in bone turnover, are preferentially 
expressed by developing bone-derived ECM.43,44 All of these proteins can be 
immobilized to the ECM structure, preserving their activity until released or until a cell 
contacts them. This allows the proteins to remain active for much longer than if they were 
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circulating in fluid, and also allows for local stimulation as the proteins are released.  
Uses in tissue engineering 
A natural polymer, ECM has been used in several tissue engineering applications 
for its biocompatibility and ability to retain proteins. The ECM can be utilized to provide 
a reliable coating on which cells can readily adhere. For example, Wang et al. have used a 
synthetic human collagen to successfully bind proteins to a polymer surface, a surface 
that usually has little affinity for protein attachment.45 Another instance of ECM 
improving upon cell-surface interaction is demonstrated by Datta et al. who used cell-
deposited ECM to enhance osteoblastic differentiation on titanium fibers.3 Cells have also 
been observed to produce ECM and a number of osteogenic factors on polymer surfaces 
of polylactic-co-glycolic acid (PLAGA) and polylactic acid (PLA).46  
A number of groups have studied the use of matrices like ECM as a delivery 
vehicle for bioactive agent delivery. The collagen fibrils of ECM naturally bind proteins 
like growth factors. In fact, bone morphogenetic protein-2 was discovered by being 
immobilized on collagen and consequently upregulating the differentiation of local 
osteoblasts.47 One unique property of ECM that could assist this approach is its well-
conserved structure across species, resulting in minimal rejection of even xenogeneic 
ECM implants.48-51 This property makes it possible to generate ECM from any number of 
sources to function as a bioactive agent delivery vehicle. 
Composite Materials: A Biologically Coated Synthetic Scaffold 
Bone derives most of its impressive mechanical strength and resilience from two 
very different components. The hard tissue of bone is reinforced by the fibrous, biological 
polymer of ECM, allowing a light and porous material to have high compressive and 
shear strength. Combining two materials for a set of properties that is more meaningful 
than either one separately was the inspiration for developing an ECM coated ceramic 
scaffold.  
A pre-laid ECM could assist cells in subsequent attachment and differentiation of 
osteoblast cells. Ideally, the ECM would be laid out, reorganized, and saturated with 
osteogenic growth factors for the second set of cells seeded on such a coated surface. The 
cell behavior enhancements that an ECM coating can provide has already been 
demonstrated on metal and polymer surfaces.3,46 Similar improvements could be seen for 
ceramic surfaces, but this combination has not been explored yet.  
The time to develop such a biological matrix on a surface has also not been 
optimized. Previous studies that generated a cell derived matrix coating on a material 
used only one development time, usually about two weeks. Would a longer or shorter 
development time affect the ECM and subsequent cell behavior in any measurable way? 
This sort of characterization has yet to be examined.  
Some preliminary experiments in our lab showed a significant increase in cell 
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number and early stage osteoblast activity biomarkers due to the presence of an ECM 
coating on ceramic scaffold surfaces. The matrix was allowed to develop for about two 
weeks, similar to other group’s attempts. Based on previous research and the early results 
collected from our own experiments, we have decided to characterize a group of ECM 
coated ceramic scaffolds using biological assays and microscopic imaging.  
Medium-soaked Scaffolds 
To compare the effects that an ECM coated scaffold has on cell behavior, a 
positive control of scaffolds soaked in osteogenic medium will be used. Calcium 
phosphate materials are known to dissolve and then reprecipitate in simulated body fluid, 
causing fluctuations in the local calcium concentration.52 The surface morphology is also 
affected by this process, lowering surface roughness. These changes could potentially 
affect cell behavior independent of any biological matrix coating. For this reason, a 
positive control group of scaffolds soaked in the same osteogenic medium used to 
generate the ECM will be examined. Any cell behavior changes due to scaffold exposure 
to a medium containing osteogenic factors and fetal bovine serum may then be identified.  
Osteoblast Precursor Cell Line 
The cells used in this experiment are W-20-17 fibroblast cells, which are 
osteoblast precursor cells derived from mouse stromal cells. The cell line is widely used 
in the characterization of osteoblast response to bone morphogenetic protein 2 (BMP-2) 
and in modeling human osteoblast cell behavior. Our lab has primarily used this cell line 
in all previous experiments, so it is well characterized from first hand use.  
These preosteoblasts have the potential to differentiate into osteoblasts, given 
certain biological signals. Confluence, or growth arrest, and the presence of a mature 
extracellular matrix are the minimum requirements for these cells to undergo 
differentiation  into osteoblast cells.11  
Osteoblasts are derived from pluripotent mesenchymal stem cells, which can 
differentiate into a variety of potential lineages.7  The preosteoblasts used here are a 
particular lineage of these stem cells on the path towards the osteoblast phenotype. Four 
categories of osteoblast function and phenotype can be described. Active osteoblasts are 
cuboidal, mononuclear cells that actively produce proteins like ALP, osteocalcin, and 
osteopontin, as well as growth factors. These are secreted from the active osteoblast into 
the osteoid, or unmineralized matrix, to promote mineral deposition of calcium and 
phosphate on the mature ECM. When osteoblasts have become surrounded by 
mineralized tissue, their function changes from generation to maintenance, and they are 
called osteocytes. The third categorization is bone-lining cells, which are neither forming 
nor resorbing bone and can be found along the surface of bone. Lastly there are inactive 
osteoblasts which are morphologically the same as bone-lining cells.7   
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Summary 
Tissue engineering faces a difficult task in bone repair. In creating a material that 
can compare with the complicated functions of bone, we looked first to identify important 
features of the natural tissue. Its composite nature seemed to be the most unique and 
influential aspect, so we used this concept to design a more robust material. A ceramic 
scaffold combined with a biologically derived polymer coating provides the benefits of a 
biomimetic synthetic ceramic and a complex natural polymer, in addition to being an 
unexplored combination of materials.  
In designing the following experiments, several unexplored factors were 
identified. Full characterization of ECM development has not been done. The time it 
would take to develop a stable three dimensional ECM structure could be important, but 
only one generation period has been explored at a time in other studies. Calcium 
phosphate is already a biocompatible surface that is composed of ionic components 
useful for osteoblast mineralization. Introducing a positive control group that has only 
been exposed to osteogenic medium will provide insight on the interaction of the scaffold 
surface and physical protein adsorption. 
Examining ECM and its effect on osteoblast behavior on a porous and 
interconnected calcium phosphate scaffold can shed light on some interesting challenges 
for tissue engineering. The concepts explored here were inspired by natural tissue, and 
similar approaches have seen success in improving the cell-surface interaction as 
measured by cell attachment and extent of differentiation. We hope that similar results 
will be found with this combination of a calcium phosphate scaffold with a unique 
architecture and cell derived coating of extracellular matrix. 
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CHAPTER 3. OBJECTIVES AND HYPOTHESES 
Objectives 
This project sought to determine the effects a cell deposited ECM coating on CaP 
scaffolds would have on preosteoblast proliferation and differentiation. Because this type 
of study has not been well characterized, the appearance and generation of the ECM will 
first be identified. To determine the extent of mineralization, cell behavior assays, and 
immunofluorescent staining, and electron microscopy was performed. The groups 
prepared for this study are summarized in Table 3.1. Sterile scaffolds were seeded with 
cells and fed osteogenic medium, gathering samples after 1, 7, 14, 21, and 28 days of 
culture (groups E1 through E28). Osteogenic medium was fed to the preosteoblasts 
generating ECM, so a positive control group of scaffolds exposed to only osteogenic 
medium was made, as well. Sterile scaffolds were given osteogenic medium and changed 
at the same time as their cell-seeded counterparts, gathering samples after 1, 7, 14, 21, 
and 28 days of medium-soaking (groups M1 through M28). 
Next, the prepared scaffolds were all seeded with preosteoblast cells to determine 
what effects the scaffold treatment had on said cells. The groups used for this experiment 
are shown in Table 3.2. A control group of autoclaved scaffolds was used for comparison. 
Also, a group of cells seeded directly onto tissue culture plates in the absence of scaffolds 
was examined. The five groups of ECM coated scaffolds prepared as previously 
described were decellularized and then gas sterilized to isolate the ECM on their surface. 
The five groups of medium-soaked scaffolds were sterilized prior to cell seeding. 
Scanning electron microscopy and cell behavior assays were used to evaluate the cell-
surface interactions. Samples were collected and measured at 1, 7, 14, 21, and 28 days. 
The hypotheses of each section are stated below.  
Table 3.1. Prepared scaffold groups. Scaffolds prepared in Stage I for further study. 
Group abbreviation Cells seeded Scaffold Days incubated 
E1 + + 1 
E7 + + 7 
E14 + + 14 
E21 + + 21 
E28 + + 28 
M1 − + 1 
M7 − + 7 
M14 − + 14 
M21 − + 21 
M28 − + 28 
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Table 3.2. Scaffold groups. Summary of scaffold groups and their treatments for use in 
Stage II. 
Group abbreviation Scaffold Treatment Purpose 
A + Autoclave sterilized Control 
C − None (cells only) Negative control 
E1 + Decellularized, gas sterilized Experimental group 
E7 + Decellularized, gas sterilized Experimental group 
E14 + Decellularized, gas sterilized Experimental group 
E21 + Decellularized, gas sterilized Experimental group 
E28 + Decellularized, gas sterilized Experimental group 
M1 + Gas sterilized Positive control 
M7 + Gas sterilized Positive control 
M14 + Gas sterilized Positive control 
M21 + Gas sterilized Positive control 
M28 + Gas sterilized Positive control 
 
Notes: All groups were seeded with cells. All scaffold groups except ‘A’ were treated 
after Stage I preparation. 
Hypotheses 
Stage I (Chapter 5) 
1. We hypothesized that the preosteoblast cells would develop more mass of 
extracellular matrix the longer they were cultured on CaP scaffolds. 
2. We hypothesized that the scaffolds soaked in cell culture medium in the 
absence of cells would have their surface properties changed by dissolution and 
reprecipitation, as well as protein adsorption from the medium. 
 
Both of these were tested qualitatively with imaging techniques. 
Stage II (Chapter 6) 
3. We hypothesized that the extracellular matrix generated from Stage I would 
enhance preosteoblast cell attachment and differentiation to the CaP scaffold 
surface compared to the sterile CaP control scaffolds. 
4. We hypothesized that the medium-soaked CaP scaffolds would enhance 
preosteoblast cell attachment and differentiation to the CaP scaffold surface 
compared to the sterile CaP control group. 
 
Cell behavior assays for cell number and cell activity were used to test these 
hypotheses. Imaging techniques were also employed to verify cell-surface interactions.  
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CHAPTER 4. BETA-TRICALCIUM PHOSPHATE SCAFFOLD 
CHARACTERIZATION 
In bone tissue engineering, the use of calcium phosphate ceramics as a synthetic 
bone graft is as strong choice due to its similarity, and consequently biocompatibility, 
with bone. A beta-tricalcium phosphate (β-TCP) scaffold with a porous, interconnected 
network has been developed by our lab. It has solid struts, and the pore size can be 
adjusted. Scanning electron microscopy confirms the pore size to range between 500 and 
750 µm. X-ray diffraction analysis confirms that the crystalline phase is primarily β-TCP 
with a minor hydroxyapatite (HA) phase. The template casting method used here 
provided scaffolds with a weight of 0.178 ± 0.015 g, diameter of 7.70 ± 0.23 mm, and 
height of 6.28 ± 0.36 mm.  
Introduction 
Biomaterials are being used to replace or enhance many different types of tissue. 
In bone tissue engineering, ceramics are being used to replace hard tissues, in coatings for 
metals, or as part of composite materials with polymers. Of the many types of ceramics 
available, the most commonly used for bone tissue repair are hydroxyapatite (HA) and 
beta-tricalcium phosphate (β-TCP). Natural bone has a crystal structure that resembles 
apatite, which is thought to contribute to the high biocompatibility of HA and β-TCP.24 
Though HA is mechanically strong and biocompatible, it has a slow degradation rate 
compared to β-TCP.25 In designing a porous, biodegradable scaffold, our lab has chosen 
to focus on the development and use of β-TCP ceramics.  
The architecture of porous scaffolds becomes very important when considering 
cell ingrowth and vascularization. Having a complete path through the bone graft allows 
bone tissue penetration and vessel recovery. Vascularization is necessary to provide 
sufficient nutrition to the regenerating tissue.53 A completely interconnected porous 
network can provide this pathway for cell development on β-TCP scaffolds.  
We are able to fabricate porous ceramic discs with solid struts, creating 
interconnected pores throughout the scaffold architecture. The pore interconnection size 
can be controlled by the use of a template casting method using sacrificial molds. The 
beta-tricalcium phosphate is converted to the desired crystal structure by high 
temperature sintering. This section will examine the crystal phase and pore structure of 
these fabricated scaffolds.  
Materials and Methods 
Scaffold fabrication 
Porous beta-tricalcium phosphate (β-TCP) scaffolds were made as described 
previously.35 Briefly, custom templates of paraffin wax were cast into plastic molds. A β-
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TCP slurry was cast into the molds by exposure to low vacuum. Excess slurry was 
removed and the cast molds were dehydrated in ethanol at an elevated temperature of 35 
to 55 °C for 48 hours. The temperature was increased to melt the wax and the scaffold 
green bodies demolded. The scaffolds were put through a graded dehydration process of 
increasing concentrations of ethanol over 8 hours and then allowed to dry for 2 hours. 
The green bodies were sintered at 1250 °C for 3 hours in a high temperature muffle 
furnace (Barnstead Thermolyne 46100). Scaffolds were cleaned in distilled (DI) water by 
ultrasonication and then autoclave sterilized prior to use.  
Morphology by scanning electron microscopy 
Scaffolds were sputter coated with gold at a thickness of 16.9 nm. Coated samples 
were imaged in a high vacuum environment at 30 kV beam energy in an FEI Quant 400 
scanning electron microscope (SEM).  
Crystal structure by X-ray diffraction 
Sintered scaffolds were crushed into powder using a mortar and pestle. The 
powder was examined in a Siemens D5000 X-ray Diffractometer. Incident angles from 30 
to 60 ° were recorded at a rate of 4.8 °/min.  
Surface area analysis by gas adsorption 
The sintered scaffold surface area was analyzed using a Micromeritics 2365 gas 
absorption machine. Nitrogen gas was used to infiltrate and fill the void spaces. The 
pressure difference between the scaffold tube and an empty control tube was used to 
calculate the surface area of scaffolds by BET analysis. 
Results 
Images gathered from the SEM machine are shown in Fig. 4.1. Pore 
interconnections ranging from 0.125 mm to 0.4 mm can be seen in the first picture, Fig. 
4.1(a). Arrows indicate pores through which another pore or pores can be seen, 
confirming the interconnected architecture of the scaffolds. A closer view of a pore 
surface in Fig. 4.1(b) shows the crystal structure of the sintered calcium phosphate 
ceramic. The continuous but tiled surface indicates crystallization of the beta-tricalcium 
phosphate material.  
The X-ray diffraction (XRD) pattern in Fig. 4.2 confirms the presence of β-TCP 
phase. Peaks at 31 ° and 34 ° in the β-TCP standard can be seen in the scaffold sample, as 
well as minor peaks at 47 ° and 52°. A standard for hydroxyapatite is also shown on the 
graph, and the scaffold sample exhibits minor HA peaks at 28° and 32.5 °.  
The BET surface area analysis showed the scaffolds to have a 0.159 ± 0.017 m2/g  
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Figure 4.1. SEM images of CaP scaffolds. Electron microscopy images of a sterile 
scaffold at (a) 50x and (b) 2,500x magnification. Arrows in (a) indicate interconnected 
pores. 
 
(a) 
(b) 
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Figure 4.2. XRD pattern. Collected diffraction pattern from a crushed β-TCP scaffold with standards for β-TCP and HA. The 
scaffold sample shares peaks with both standards, indicating the presence of both phases. 
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surface area. A material density of 3.140 g/cm3, the density of pure β-TCP, was used for 
calculating the surface area.  
Discussion 
The interconnected network in the scaffolds provides structural support for the β-
TCP scaffolds as well as a necessary pathway for cell proliferation. Other researchers 
have used pore interconnection diameters ranging from 100 to 500 µm, and the scaffolds 
examined here are of similar size. Studies show that a minimum pore interconnection size 
of 100 µm is needed for preosteoblast penetration, but pore interconnections must be 
larger than 300 µm to allow for full vascularization.32 The SEM images suggest that 
preosteoblasts seeded on the scaffold surface will be able to develop and attach to the 
porous CaP scaffold without being limited by pore interconnection size.  
A stochiometric β-TCP powder was used to create the scaffolds. After sintering, 
the material was expected to be crystallized into a β-TCP form. Comparison to standards 
of β-TCP and HA show that the scaffold material is primarily β-TCP with a minor phase 
of HA.35  
The gas adsorption method is very sensitive to surface roughness, since the 
nitrogen molecules can fill spaces much smaller than are usable by cells. The BET 
method of analysis is used to find the specific surface area, which accounts for very small 
variations in the surface. Thus, the surface area measured is actually much higher than is 
physically usable. The method used here measures a single layer of gas on the surface of 
the ceramic. Using this method of analysis to calculate the surface area of a typical CaP 
scaffold weighing 0.2 g gives a surface area of 318 cm2. For comparison, each well of a 
24 well plate has a surface area of 2 cm2, and these 24 well plates are used for all cell 
culture work with the CaP scaffolds. Again, it is likely that the calculated surface area is 
much higher than what is actually usable by cells.  
Conclusion 
The porous scaffolds created here are appropriate for use in tissue engineering 
applications. Our own previous studies have shown the biocompatibility of the scaffolds 
using W-20-17 mouse preosteoblast cells. The performance of the porous β-TCP 
scaffolds are examined in vitro in the following chapters. 
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CHAPTER 5. GENERATING EXTRACELULLAR MATRIX ON BETA-
TRICALCIUM PHOSPHATE SCAFFOLDS 
In bone tissue engineering, synthetic materials may be used in place of autograft 
or allograft tissue. This would provide a similar scaffold function without the need for a 
second surgery to harvest tissue as in autografts, or remove the risk of disease 
transmission that is present in allograft surgeries. One such synthetic material is calcium 
phosphate ceramics, which can be treated and shaped to fit large bone defects. Ceramic 
scaffolds used for treatment of large bone defects stimulate osteogenesis in critical sized 
defects. Though the materials are not osteoinductive, the proximity to healthy tissue 
allows the ceramic to function as a continuous scaffold for cells to attach and proliferate, 
resulting in bone tissue regeneration. A cell-deposited extracellular matrix (ECM) on the 
porous beta-tricalcium phosphate (β-TCP) scaffolds could enhance subsequent cell 
seeding. Scaffolds were seeded with W-20-17 cells and cultured in osteogenic medium 
for 28 days. Samples were removed at days 1, 7, 14, 21, & 28 days to measure ECM by 
looking for the presence of collagen type I, the most abundant protein found in all types 
of ECM. Scaffolds were decellularized to isolate the ECM coating on scaffolds. 
Immunofluorescence and electron microscopy were done to visualize the scaffold 
surfaces. Alkaline phosphatase, total protein, and double stranded DNA assays were 
performed to ensure osteoblast differentiation on the scaffolds. ECM deposition can be 
clearly seen after 14 days. The medium-soaked group exhibited smoother surface 
morphology over time. Varying amounts of ECM, increasing with time, were successfully 
generated and maintained on β-TCP scaffolds after decellularization. 
Introduction 
Large bone defects are treated with bone grafts at a rate of approximately 1.5 
million operations per year in the United States.1 The primary methods of treatment 
include autografts and allografts. Both of these treatments suffer from a lack of tissue 
supply, and they also require multiple surgeries to gather the necessary tissue and perform 
the implantantion.  
Synthetic biomaterials can provide the same beneficial effects of autograft bone 
tissues without the limit of supply. The goal of these synthetic materials is to create a 
substance that can generate a cell response similar to natural bone. The material must be 
biocompatible, biodegradable, and ideally osteoinductive. Ceramic and polymer materials 
tend to be osteoconductive rather than inductive, but cells readily attach and begin 
proliferation and differentiation on their surfaces.  
Our lab focuses on beta-tricalcium phosphate (β-TCP) ceramic materials 
constructed by a casting and sintering method. The scaffolds have interconnected pores 
and possess the qualities mentioned before, being biocompatible, biodegradable, and 
osteoconductive. In order to improve the healing rate of the scaffolds, a cell-deposited 
layer of extracellular matrix (ECM) will be prelaid prior to use. Datta et al. have shown 
that ECM synthesized on titanium constructs prior to seeding with marrow stromal cells 
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can enhance osteoblastic differentiation.3 We expect that a similar result will be seen on 
ceramic scaffolds with an ECM synthesized prior to cell seeding.  
The process of depositing the ECM has not been fully characterized in our lab. 
We will examine the extent of ECM deposition over a 28 day period to determine an 
optimal time for culture. The ceramic scaffolds seeded with osteoblast precursor cells will 
be cultured with osteogenic medium. Samples and data will be collected every week 
during the study. Qualitative analysis of the ECM will be examined as well as the 
behavior of the cells depositing the ECM.  
The goal is to confirm the ECM deposition on scaffolds, determine the effects of 
decellularization on the ECM, and finally define the starting parameters for the following 
experiments, which will examine effects on cell behavior due to a cell-synthesized ECM 
on β-TCP scaffolds. 
Materials and Methods 
All cell culture materials were purchased from Invitrogen unless otherwise noted. 
Control medium was made with 10% fetal bovine serum (FBS, #16000-044) in 
Dulbecco's modified Eagle medium (DMEM, #10313-039) with 1% antibiotic-
antimycotic (PSA, #15240-062) and 1% L-glutamine (#25030-081).  
Osteogenic medium was made by adding 50 mg/L of ascorbic acid (Sigma 
#A4544), 1.0 × 10-8 M dexamethasone (Fisher #AC23030-0050), and 0.01 M beta-
glycerophosphate (Fisher #ICN15724150) to the control medium formula.  
The W-20-17 mouse preosteoblast cells were obtained from ATCC. Primary 
antibody was obtained from Abcam (ab299999) and secondary antibody was purchased 
from Invitrogen (#A11008). Chemicals for the assays and bovine serum albumin (BSA) 
were purchased from Sigma unless otherwise noted. Scaffolds were fabricated in lab prior 
to use as described previously.35 
Scaffold fabrication 
Porous beta-tricalcium phosphate (β-TCP) scaffolds were made as described 
previously.35 Briefly, custom templates of paraffin wax were cast into plastic molds. A β-
TCP slurry was cast into the molds by exposure to low vacuum. Excess slurry was 
removed and the cast molds were dehydrated in ethanol at an elevated temperature of 35 
to 55 °C for 48 hours. The temperature was increased to melt the wax and the scaffold 
green bodies demolded. The scaffolds were put through a graded dehydration process of 
increasing concentrations of ethanol over 8 hours and then allowed to dry for 2 hours. 
The green bodies were sintered at 1250 °C for 3 hours in a high temperature muffle 
furnace (Barnstead Thermolyne 46100). Scaffolds were cleaned in DI water by 
ultrasonication and then autoclave sterilized prior to use.  
Scaffolds used in this experiment weighed 0.178 ± 0.015 g with a diameter of 
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7.70 ± 0.23 mm and height of 6.28 ± 0.36 mm.  
Cell culture 
The W-20-17 cells were reconstituted from frozen stock. Cells were cultured in T-
75 plates using control medium. Cells were incubated at 37 °C in a 5% CO2 atmosphere 
and fed control medium every 3 to 4 days. Prior to seeding on scaffolds, cells were 
trypsinized for 2 minutes at 37 °C and diluted in control medium to the desired 
concentration. Cells were counted in a Coulter counter (Beckman Coulter Z2). 
Development of extracellular matrix coating 
Autoclaved scaffolds were placed in 24 well plates. An aliquot of approximately 
50 µL control medium containing 1.0 × 105 W-20-17 cells was placed onto each scaffold. 
The cell solution and scaffold were incubated for 1 hour at 37 °C in a 5% CO2 
atmosphere. Then 2 mL of osteogenic medium was added to each scaffold well. The cells 
were cultured for 28 days. Osteogenic medium was changed every 3 days for the first 2 
weeks and every 2 days after that. Samples were collected at days 1, 7, 14, 21, and 28 by 
removing medium and rinsing twice with phosphate buffered saline (PBS), then storing at 
-20 °C. Samples were seeded in duplicate 3 days apart and the sample readings were 
combined (n = 30). 
Medium-soaked scaffolds 
Another set of autoclaved scaffolds was prepared and soaked in 2 mL osteogenic 
medium for 28 days. Scaffolds were kept at 37 °C in a 5% CO2 atmosphere. The 
scaffolds were kept in these conditions for 28 days, changing medium every 3 days for 
the first 2 weeks and every 2 days after that. Samples were collected at days 1, 7, 14, 21, 
and 28 by removing medium and rinsing twice with PBS, then storing at -20 °C. Samples 
were seeded in duplicate 3 days apart and the sample readings were combined (n = 30). 
Immunofluorescence of extracellular matrix  
Collagen type I was used as an indicator of ECM presence. After being collected 
from culture, scaffolds were brought to room temperature from -20 °C and fixed in 4% 
paraformaldehyde for 15 min. They were rinsed twice with PBS and blocked with 10% 
goat serum in 1% BSA-PBS for 30 min. The blocking agent was removed and scaffolds 
were submerged overnight at 4 °C in a 1:100 dilution of a mouse collagen type I antibody 
raised in rabbit. Scaffolds were rinsed twice with PBS and then immersed in a 1:250 
dilution of Alexa Fluor 488, an anti-rabbit fluorescein conjugated secondary antibody 
raised in goat, for 1 hr at room temperature protected from light. Samples were rinsed 
twice with PBS and observed under a fluorescence microscope (Nikon TE2000-U).  
This immunohistology was performed on thin versions of scaffolds approximately 
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half the weight and height of scaffolds used for quantification. The thin scaffolds weighed 
0.085 ± 0.009 g and had a diameter of 8.11 ± 0.27 mm by 3.50 ± 0.25 mm height. Half 
the number of cells (5 × 104) was seeded onto these scaffolds, and half the volume of 
medium (1 mL) was used during feeding and culture. The decreased thickness allowed 
the scaffolds to be viewed under a microscope without the opaque β-TCP struts blocking 
light for viewing and recording images.  
Scanning electron microscopy of scaffolds 
Scaffolds were decellularized by rapid freeze-thaw cycling and rinsing with 0.2% 
triton. Scaffolds were fixed for 15 min using 4% paraformaldehyde and allowed to dry 
overnight. Using a sputter coater, samples were plasma sprayed with gold to be imaged 
with electron microscopy. An FEI Quanta 400 scanning electron microscope was used for 
all imaging, set to high vacuum mode and 30 kV beam energy.  
Cellular behavior assays 
At the end of cell culture and after rinsing, all scaffolds were moved to new plates 
and all samples were decellularized. The decellularization process had 700 µL of 0.2% 
triton added to isolated scaffolds and their previous wells. The plates all went through 
rapid freeze-thaw cycling, which consisted of 3 cycles of -80 °C incubation for 20 
minutes immediately followed by 37 °C incubation for 15 minutes. The scaffolds were 
ultrasonicated for 5 minutes to collect cellular debris (n = 30), while the well remains 
without scaffolds were scraped to dislodge and collect cellular debris (n = 30).  
The cell lysate collected was tested for double stranded DNA, which can be 
measured to estimate cell number. A Quant-iT PicoGreen assay kit (Invitrogen # P11496) 
was used according to the manufacturer's instructions. Briefly, 50 μL samples were added 
in duplicate to opaque 96 well microplates. An equal volume of a 1:200 dilution of 
picogreen was added to each well in the dark. After 5 min, plates were read in a BioTek 
FLx800 plate reader at 485 nm excitation and 530 nm emission. Standard curves were 
made using the provided dsDNA samples. 
The cell lysate from decellularized scaffolds was also measured for the presence 
of alkaline phosphatase (ALP), an early stage indicator of osteoblast differentiation. Fifty 
μL of each sample were added in duplicate to 96 well microplates. Each sample had 50 
μL of working solution, made of equal volumes 20 mM p-nitrophenyl phosphate (PNPP), 
1.5 M 2-amino-2-methyl-1-propanol, and 1.0 mM MgCl2, added to it. Plates were 
incubated at 37 °C for 1 hr. The reaction was stopped by placing plates on ice and adding 
100 μL of 1 M NaOH. A Bio Rad model 680 microplate reader was used to measure the 
absorbance at 405 nm. For a standard, p-nitrophenol (PNP) was used. 
A bicinchoninic acid (BCA) assay was run on cell lysate samples to measure total 
protein using a microBCA kit (Thermo Fisher #23235). Samples from days 7, 14, 21, and 
28 were diluted 5x, while day 1 samples were measured undiluted. In duplicate, 130 µL 
of sample were added to 96 well microplates. Working reagent was prepared fresh 
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according to manufacturer’s instructions and 130 µL was added to each well. Plates were 
gently shaken, covered, and incubated at 37 °C for 2 hrs. Plates were then brought to 
room temperature and the absorbance at 562 nm measured with a microplate reader. 
Standard curves were made using the provided bovine serum albumin (BSA). 
Statistical analysis 
Results are reported and shown on plots as average ± one standard deviation.  
Results 
Fig. 5.1 shows images of the scaffolds after immunofluorescent staining. A pair of 
images was taken using the brightfield for comparison, seen in Fig. 5.1(a) and Fig. 
5.1(b). Because no cells were present to generate ECM on the untreated scaffold, the 
fluorescent image in Fig. 5.1(c) appears dark. The green appearance in Fig. 5.2(d) results 
from the fluorescein conjugated secondary antibody bound to mouse collagen type I 
primary antibody reacting with a fluorescent lamp, filtered to provide excited light at 495 
nm. The fluorescein conjugate emits light at 419 nm, giving a green appearance. The 
transparent sheet of cells indicated by a white arrow in Fig. 5.1(b) is clearly seen to 
fluoresce in Fig. 5.1(d), also marked by a white arrow. This suggests the presence of 
collagen type I, a major component of extracellular matrix. The microscope camera took 
pictures in grayscale, so fluorescent images were pseudocolored for effect.  
SEM images of decellularized scaffolds were taken at high magnification, as seen 
in Fig. 5.2. The untreated scaffold surface can be seen at 1,000x in Fig. 5.2(a). Following 
it are images of scaffolds seeded with cells over the 28 day culture period. On day 14, 
Fig. 5.2(d), cell depositions can be seen as thin fibers along the ceramic surface. They are 
marked by black arrows. By day 21, Fig. 5.2(e), fibers have begun to cross pores and are 
thicker than in the day 14 scaffold. On day 28, Fig. 5.2(f), the fibers can still be seen 
crossing between struts of ceramic material, and also sheets of cell matrix can be seen 
forming along the calcium phosphate surface, indicated by a black arrow.  
Fig. 5.3 shows the cell behavior data collected from cell lysate over the 28 day 
preparation time. The first column, Fig. 5.3(a), Fig. 5.3(c), and Fig. 5.3(e) were collected 
and measured from cells on the scaffold surface. The second column, Fig. 5.3(b), Fig. 
5.4(d), and Fig. 5.3(f), were collected and measured from the cells remaining in the wells 
of cultured scaffolds. Cells were separated in this way to determine if any changes could 
be observed between cells attached to the scaffold surface and cells attached to the tissue 
culture plate surface. 
The dsDNA plots represent the total number of cells from each group at a given 
time point. The scaffold group, Fig. 5.3(a), shows a plateau after day 7, while the well 
remains group, Fig. 5.3(b), plateaus at day 14. This suggests that cells on the scaffolds 
reached confluence more quickly than cells that had migrated or initially attached to the 
tissue culture plate surface.  
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Figure 5.1. Immunofluorescent staining. Brightfield images at 40x are shown of an 
untreated scaffold (a) and 28 day cell cultured scaffold (b). Respective fluorescent images 
at 40x are shown below that for the untreated (c) and 28 day cell cultured (d) scaffolds. A 
green fluorescent secondary antibody gives collagen a green appearance when viewed 
with a 419 nm filter. The arrows indicate cell deposited matrix. 
 
 
(a) 
(b) 
(b) 
(c) (d) 
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Figure 5.2. SEM Images of ECM development. The progression of cells depositing 
extracellular matrix is shown at 1,000x magnification. Image (a) shows an untreated 
scaffold. Cell seeded samples were imaged after 1 (b), 7 (c), 14 (d), 21 (e), and 28 (f) 
days of culture. Arrows indicate cell matrix growth. 
(a) (b) 
(c) (d) 
(e) (f) 
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Figure 5.3. Cell behavior assays for cells on scaffold. Plots of data collected from 
scaffolds (a), (c), (e) and the well remains (b), (d), (f). Total dsDNA is shown in (a) and 
(b). Normalized ALP production per cell is shown in (c) and (d). Normalized total protein 
per cell is shown in (e) and (f). Data represent means ± standard deviatio (n = 30) except 
(e) & (f) where (n = 18). 
 
(a) (b) 
(c) (d) 
(e) (f) 
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Next, the ALP per dsDNA plots are shown. Alkaline phosphatase is an early stage 
marker for osteoblast differentiation, and these plots are normalized to cell number to 
indicate the ALP production per cell. The scaffold group, Fig. 5.3(c), shows a stable 
production of ALP per cell for the duration, while an increasing amount of ALP per cell 
can be seen in the well remains group, Fig. 5.3(d). Following a peak in ALP production, 
cells are said to have begun osteoblast differentiation. However, no such peak was seen in 
either group.  
Finally, the total protein per dsDNA plots represent the activity of measured cells. 
The assay measures all protein present in the cell lysate, and that value was also 
normalized to cell number with the dsDNA count. The cells collected from scaffolds, Fig. 
5.3(e), suggest a consistent level of activity over the 28 day culture period. However, the 
cells left in the well, Fig. 5.3(f), show a high reading on the first day, followed by a sharp 
drop by day 7, and a steadily increasing protein production per cell over time. The high 
value on day 1 is likely an artifact of several factors, discussed later. 
Discussion 
The SEM images collected show that a cell derived matrix has been deposited 
after 14 days. The immunofluorescence images reinforce this with a depiction of cell 
matrix after 28 days of culture, and the cell behavior data also agrees with this by 
showing a plateau in cell number prior to this time.  
The images of the scaffolds visibly show a cell derived coating of ECM on the 
scaffolds even after decellularization. That coating will be used to measure cell behavior 
when preosteoblasts are reseeded on the same scaffolds.  
From the dsDNA data, a near zero cell number count for well remains on day 1 
can be seen. The cell count then quickly increases to the same magnitude of the scaffolds 
within two weeks. The well remains represent cells that have migrated out from the 
scaffold, or were not well attached after the 1 hour incubation period but remained viable 
after adding the medium. Such a low value here suggests a high attachment rate of cells 
to the scaffold during the initial seeding. 
The high reading on day one of total protein per dsDNA is likely an artifact of two 
confounding factors. The low dsDNA count on day one, coupled with the fact that the 
tissue culture plates are coated with fibronectin proteins, would give an artificially high 
reading not representative of actual cell behavior. The protein count at this time point 
likely includes the tissue culture plate coating, and dividing it by a low cell number 
results in a higher than expected value.  
An increasing amount of ALP per dsDNA with time can be observed for the well 
remains groups. However, the cells on the scaffolds show a relatively low ALP 
production throughout the 28 days. Within two weeks of cell confluence, preosteoblasts 
that have begun differentiation towards mature osteoblasts show a peak in ALP 
production per cell. This was not observed, despite confluence being achieved at 7 or 14 
days from cell seeding. The higher ALP production in the well remains group would 
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normally indicate more cells at a later stage of differentiation, but no ALP peak was 
observed in either group. We would expect higher amounts of ECM to be deposited by 
more mature osteoblasts, as the development of ECM is an important step towards 
generating mineralized tissue.11  
The low amount of ALP from lysed cells on the scaffolds could be a result of the 
protein being retained in the ECM, giving a lower measurement even at later time points. 
Regardless, the cells in either group are producing ALP, and the total protein per dsDNA 
plots show that the cells are active throughout the 28 day culture period. Qualitative 
imaging confirms a cell deposition on the scaffold surface, but the cell behavior data does 
not allow a statement to be made about the mineralization of the observed cell matrix.  
Conclusion 
The porous TCP scaffolds can be successfully coated in a cell-secreted ECM 
coating after 14 days. The coating is still visible after the decellularization process. The 
scaffolds prepared here are sufficient for further examination of the effects the cell 
derived matrix may have on subsequent cell seeding.  
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CHAPTER 6. PREOSTEOBLAST BEHAVIOR ON SCAFFOLDS COATED WITH 
EXTRACELLULAR MATRIX 
Bone grafts are commonly used for the treatment of large bone defects. 
Biodegradable, synthetic bone grafts combined with cells and growth factors as a tissue 
engineered construct can provide benefits over the common autografts and allografts 
currently used. Calcium phosphate materials offer high biocompatibility and chemical 
similarity to natural bone tissue. Biodegradable beta-tricalcium phosphate (β-TCP) 
scaffolds with an interconnected porous network have been created to promote tissue 
ingrowth and regeneration in vitro and in vivo. Extracellular matrix (ECM) coated on 
titanium and polymer scaffolds improved cell response. Here, we attempted to further 
improve the biocompatibility of the interconnected β-TCP ceramic scaffolds by 
generating a cell derived ECM on the ceramic surface in vitro. Cell derived ECM was 
generated on scaffolds for 1, 7, 14, 21, or 28 days. Osteogenic medium-soaked scaffolds 
treated for the same time periods as ECM coated scaffolds and autoclaved, untreated 
scaffolds were used as controls. The behavior of preosteoblasts seeded onto each scaffold 
was examined over a 28 day period. Cellular assays for cell number, alkaline phosphatase 
(ALP), and total protein (TP) were measured. Cell morphology changes on the scaffold 
were observed by scanning electron microscopy. The cell count on all scaffolds reached a 
plateau after 14 days. Specific ALP and specific TP slowly increased during the 28 days 
for all groups. New ECM was visible after 14 days of generation time on all groups. No 
significant difference was seen between the eleven tested scaffold groups. This study 
verified the high biocompatibility of β-TCP scaffolds and suggested that a cell derived 
biological coating on the β-TCP scaffolds offers no significant changes to the 
differentiation or attachment rates of cells.  
Introduction 
Bone grafts are commonly used for the treatment of large bone defects. The 
primary methods of treatment, autografts and allografts, are limited by supply and the 
need for multiple surgeries, among other complications. Synthetic bone materials address 
these issues and can provide more specialized functions in bone tissue repair. 
Tissue engineering designs aim to create implants that can improve the healing 
rate and tissue integration of a wound site. In long bone repair, the time to recovery can 
take weeks due to the relatively slow process of bone regeneration across a void. 
Particularly in large bone voids, cases exist where no regeneration would occur unless a 
graft is implanted. Though a porous, biodegradable beta-tricalcium phosphate (β-TCP) 
scaffold can successfully bridge a bone void and promote tissue regeneration even in 
critical sized defects, methods of accelerating the bone healing rate are always under 
investigation.  
In natural bones, the extracellular matrix (ECM) that permeates the hard tissue 
provides torsional resistance and shock absorbing qualities to it. The naturally composite 
tissue possesses high compressive and shear strengths while maintaining a low weight 
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and a porous interior structure. In trying to mimic the tissue being replaced, composite 
materials can provide the combination of polymer and ceramic properties that makes 
bone unique.  
In addition, the ECM naturally retains osteogenic proteins and is a primary 
structure in the mineralization of developing bone tissue. All of these roles of the two 
different components of bone inspired the approach of adding a cell derived ECM coating 
to synthetic, porous, β-TCP scaffolds. Due to the already biomimetic nature of calcium 
phosphate materials, a biological polymer coating of ECM has been proposed to enhance 
tissue regeneration.  
Previous studies have found favorable results in cell proliferation and 
differentiation when an ECM coating was used on metal and polymer surfaces.3,46 Similar 
increases in cell attachment and differentiation are expected for an ECM coating on β-
TCP scaffolds.  
Little work has been done to characterize or optimize the ECM coating of other 
materials. Only one time period is chosen to allow cells to deposit their ECM on a 
surface. Examining the effects of ECM generated after 1, 7, 14, 21, or 28 days on the β-
TCP scaffolds may provide an optimal growth time to improve subsequent cell seeding.  
This experiment will examine the effects an ECM coating of β-TCP scaffolds has 
on preosteoblast behavior. Scanning electron microscopy and cellular assays for cell 
number and alkaline phosphatase (ALP), an early stage biomarker for osteoblast 
differentiation, will be used to characterize the cells. As a positive control, scaffolds 
soaked in medium for 1, 7, 14, 21, or 28 days without seeded cells will be examined. This 
control will be useful to compare the effect prolonged immersion has on the cell-surface 
interaction, independent of the matrix coating.  
The goal is to determine what biological changes in cell behavior result from 
having an ECM coating on β-TCP scaffolds. Control groups will use medium-soaked 
scaffolds, untreated scaffolds, and cells cultured in osteogenic medium on tissue culture 
plates.  
Materials and Methods 
All cell culture materials were purchased from Invitrogen unless otherwise noted. 
Control medium was made with 10% fetal bovine serum (FBS, #16000-044) in 
Dulbecco's modified Eagle medium (DMEM, #10313-039) with 1% antibiotic-
antimycotic (PSA, #15240-062) and 1% L-glutamine (#25030-081).  
Osteogenic medium was made by adding 50 mg/L of ascorbic acid (Sigma 
#A4544), 1.0 × 10-8 M dexamethasone (Fisher #AC23030-0050), and 0.01 M beta-
glycerophosphate (Fisher #ICN15724150) to the control medium formula.  
The W-20-17 mouse preosteoblast cells were obtained from ATCC. Primary 
antibody was obtained from Abcam (ab299999) and secondary antibody was purchased 
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from Invitrogen (#A11008). Chemicals for the assays and bovine serum albumin (BSA) 
were purchased from Sigma unless otherwise noted. Scaffolds were fabricated in lab prior 
to use as described previously.35 
Scaffold fabrication 
Porous beta-tricalcium phosphate (β-TCP) scaffolds were made as described 
previously.35 Briefly, custom templates of paraffin wax were cast into plastic molds. A β-
TCP slurry was cast into the molds by exposure to low vacuum. Excess slurry was 
removed and the cast molds were dehydrated in ethanol at an elevated temperature of 35 
to 55 °C for 48 hours. The temperature was increased to melt the wax and the scaffold 
green bodies demolded. The scaffolds were put through a graded dehydration process of 
increasing concentrations of ethanol over 8 hours and then allowed to dry for 2 hours. 
The green bodies were sintered at 1250 °C for 3 hours in a high temperature muffle 
furnace (Barnstead Thermolyne 46100). Scaffolds were cleaned in DI water by 
ultrasonication and then autoclave sterilized prior to use.  
Cell culture 
The W-20-17 cells were reconstituted from frozen stock. Cells were cultured in T-
75 plates using control medium. Cells were incubated at 37 °C in a 5% CO2 atmosphere 
and fed control medium every 3 to 4 days. Prior to seeding on scaffolds, cells were 
trypsinized for 2 minutes at 37 °C and diluted in control medium to the desired 
concentration. Cells were counted in a Coulter counter (Beckman Coulter Z2). 
Preparation of scaffolds 
Two groups of scaffolds were prepared one month before the study began. The 
experimental group had an extracellular matrix produced by seeded cells for up to 28 
days. A control group of scaffolds had no exposure to cells but was submerged in 
osteogenic medium for the same length of time as the experimental group. Scaffolds were 
prepared in 24 well plates for this process. Prior to processing, these scaffolds weighed 
0.178 ± 0.015 g with a diameter of 7.70 ± 0.23 mm and height of 6.28 ± 0.36 mm.  
To produce the ECM on scaffolds, autoclaved scaffolds were placed in 24 well 
plates. An aliquot of approximately 50 µL control medium containing 1.0 × 105 W-20-17 
cells was placed onto each scaffold. The cell solution and scaffold were incubated for 1 
hour at 37 °C in a 5% CO2 atmosphere. Then 2 mL of osteogenic medium was added to 
each scaffold well. The cells were cultured for 28 days. Osteogenic medium was changed 
every 3 days for the first 2 weeks and every 2 days after that. Samples were collected at 
days 1, 7, 14, 21, and 28 by removing medium and rinsing twice with phosphate buffered 
saline (PBS), then storing at -20 °C. After all samples had been collected, rapid freeze-
thaw cycling was performed to decellularize the ECM coated scaffolds. First a detergent, 
700 µL of 0.2% triton in DI water, was added to each scaffold, and samples were 
incubated for 1 hr at 4 °C. Samples were cycled three times between -80 °C for 20 min 
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and 37 °C for 15 min. Scaffolds were ultrasonicated for 5 min to remove cellular debris, 
then the detergent was removed. Samples were rinsed twice with PBS, and then allowed 
to dry. All samples were sterilized with ethylene oxide gas prior to use. 
Medium-soaked scaffolds were similarly prepared. Another set of autoclaved 
scaffolds was soaked in 2 mL osteogenic medium. Scaffolds were kept at 37 °C in a 5% 
CO2 atmosphere. The scaffolds were kept in these conditions for 28 days, changing 
osteogenic medium every 3 days for the first 2 weeks and every 2 days after that. 
Samples were collected at days 1, 7, 14, 21, and 28 by removing medium and rinsing 
twice with phosphate buffered saline (PBS), then storing at -20 °C. Samples were thawed, 
dried, and sterilized with ethylene oxide gas. 
Cell seeding on scaffolds 
Scaffolds were separated into 24 well plates according to collection time. 
Scaffolds previously prepared over a 28 day period consisted of two experimental 
treatments, scaffolds seeded and cultured with cells and scaffolds soaked in osteogenic 
medium. Each treatment had scaffolds collected at days 1, 7, 14, 21, and 28. This totaled 
10 groups, five time points for both ECM coated scaffolds and medium-soaked scaffolds. 
An eleventh group of scaffolds was prepared and not treated except by autoclave 
sterilization to function as a scaffold surface control.  
On day 0, all scaffolds were seeded with 1.0 × 105 W-20-17 cells at passage 9 in a 
50 µL aliquot. The cell solution and scaffold were incubated for 1 hour at 37 °C in a 5% 
CO2 atmosphere. Then 2 mL of osteogenic medium was added to each scaffold well. The 
cells were cultured for 28 days. Osteogenic medium was changed every 3 days for the 
first 2 weeks and every 2 days after that. Samples were collected at days 1, 7, 14, 21, and 
28 by removing medium and rinsing twice with PBS, then storing at -20 °C.  
A twelfth group consisting of cells seeded directly on tissue culture plates was 
also started to serve as a cell behavior control. Each well was seeded with 1.0 × 105 W-
20-17 cells at passage 9 in a 50 µL aliquot. Then 1 mL of osteogenic medium was added 
to each well. The cells were cultured at 37 °C in a 5% CO2 atmosphere for 28 days. 
Osteogenic medium was changed every 3 days for the first 2 weeks and every 2 days 
after that. Samples were collected at days 1, 7, 14, 21, and 28 by removing medium and 
rinsing twice with PBS, then storing at -20 °C.  
The cell culture was performed in duplicate, seeded three days apart. Each of the 
twelve groups had a total of 6 scaffolds (or wells in the case of the cells on tissue culture 
plates) to be measured at each time point (n = 6).  
Cellular behavior assays 
At the end of cell culture and after rinsing, all scaffolds were moved to new 
plates. The isolated scaffolds and their previous wells had 700 µL of 0.2% triton added to 
them. The plates all went through rapid freeze-thaw cycling. The scaffolds were 
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ultrasonicated for 5 minutes to collect cellular debris (n = 6), while the well remains 
without scaffolds were scraped to dislodge and collect cellular debris (n = 6).  
The cell lysate collected was tested for double stranded DNA, which can be 
measured to estimate cell number. A Quant-iT PicoGreen assay kit (Invitrogen # P11496) 
was used according to the manufacturer's instructions. Briefly, 50 μL samples were added 
in duplicate to opaque 96 well microplates. An equal volume of a 1:200 dilution of 
picogreen was added to each well in the dark. After 5 min, plates were read in a BioTek 
FLx800 plate reader at 485 nm excitation and 530 nm emission. Standard curves were 
made using the provided dsDNA samples. 
The cell lysate from decellularized scaffolds was measured for the presence of 
alkaline phosphatase (ALP), an early stage indicator of osteoblast differentiation. Fifty μL 
of each sample were added in duplicate to 96 well microplates. Each sample had 50 μL of 
working solution, made of equal volumes 20 mM p-nitrophenyl phosphate (PNPP), 1.5 M 
2-amino-2-methyl-1-propanol, and 1.0 mM MgCl2, added to it. Plates were incubated at 
37 °C for 1 hr. The reaction was stopped by placing plates on ice and adding 100 μL of 1 
M NaOH. A Bio Rad model 680 microplate reader was used to measure the absorbance at 
405 nm. For a standard, p-nitrophenol (PNP) was used. 
A bicinchoninic acid (BCA) assay was run on cell lysate samples to measure total 
protein using a microBCA assay kit (Thermo Fisher #23235). Samples from days 7, 14, 
21, and 28 were diluted 5x, while day 1 samples were measured undiluted. In duplicate, 
130 µL of sample were added to 96 well microplates. Working reagent was prepared 
fresh according to manufacturer’s instructions and 130 µL was added to each well. Plates 
were gently shaken, covered, and incubated at 37 °C for 2 hrs. Plates were then brought 
to room temperature and the absorbance at 562 nm measured with a microplate reader. 
Standard curves were made using the provided bovine serum albumin (BSA). 
Scanning electron microscopy of scaffolds 
Some scaffolds were set aside for imaging without decellularization. These 
scaffolds were brought to room temperature from -20 °C, then fixed for 15 min using 4% 
paraformaldehyde. Samples were rinsed twice in PBS and allowed to dry overnight. 
Using a sputter coater, samples were plasma sprayed with gold to be imaged with 
electron microscopy. An FEI Quanta 400 scanning electron microscope was used for all 
imaging, set to high vacuum mode and 30 kV beam energy.  
Statistical analysis 
Results are reported as average ± standard deviation. As described before, all 
measurements were performed twice. Results are considered significantly different if the 
p-value < 0.05. Two-way ANOVA was performed on data groups and time. Significance 
was tested pairwise using the Holm-Sidak method. 
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Results 
The results of the cell behavior assays are shown below in Fig. 6.1 through 6.6, 
with odd numbered figures corresponding to measurements taken from cells on the 
scaffold surface and even numbered figures for the measurements from cells remaining in 
the well after isolating the scaffold. In each plot, the legend lists the control group(s) first, 
followed by the experimental groups. For each time point, the vertical bars represent 
those same groups, in the order they are listed, from left to right.  
For plots titled “from scaffolds,” all group abbreviations end in ‘S’ to indicate the 
measurements were taken from cells on the scaffold surface. The first letter indicates 
from which group of scaffolds the cells were collected. The ‘AS’ group represents the 
control group of autoclaved, untreated scaffolds. Groups labeled ‘ExxS’ are from the 
ECM coated group, with the number in the middle (where ‘xx’ is 1, 7, 14, 21, or 28) 
telling the number of days the scaffold was allowed to culture before being frozen, 
decellularized, and sterilized prior to seeding again. The ‘MxxS’ groups represent the 
medium-soaked scaffolds, also with the number stating how many days the scaffold was 
prepared before being frozen, sterilized, and then seeded in this experiment.  
The plots titled “from well remains” have an extra group, ‘C,’ that was collected 
from cells seeded directly onto tissue culture plates in the absence of any scaffold. The 
other groups had a scaffold in the well until decellularization, and end in ‘W’ to represent 
this. Here, the ‘AW’ group was result of cells remaining in the well of the untreated, 
autoclaved control scaffold; the ‘ExxW’ group are the well remains of the scaffolds 
cultured for the indicated number of days (where ‘xx’ is 1, 7, 14, 21, or 28) before 
beginning this experiment; and the ‘MxxW’ group is the well remains of scaffolds soaked 
in medium for the indicated number of days before beginning this experiment.  
Though the measurements for cells on the scaffolds and cells remaining in the 
wells were done separately, the cells that were found in the wells were a direct result of 
cell migration from the seeded scaffolds.  
In all plots, the asterisk (*) indicates a significant difference (p-value < 0.05) 
between the indicated group and the AS or AW control group. Significance between time 
points is pointed out in the figure descriptions. 
The dsDNA assays, which represent cell number from each source, are shown 
first. In Fig. 6.1, the cells from all scaffold groups can be seen to plateau after 14 days. 
There was no significant difference amongst any of the scaffold groups. On day 7, group 
E14S was about the same magnitude as day 1. A problem with cell seeding likely caused 
this low reading. A plateau had been reached at day 14, as no significant difference was 
seen between time points 14, 21, and 28. In Fig. 6.2, the cell culture control group, C, had 
a very high count on day 1 compared to the other 11 groups. Because the cells were 
seeded directly onto the plate surface, the dsDNA count is very high at this time, whereas 
the well remains of scaffolds must migrate out of the scaffold and into the well. The low 
number of cells in the wells this early suggests a high retention of seeded cells across all 
scaffold groups. As with the cells from scaffolds, none of the groups were significantly  
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Figure 6.1. dsDNA from scaffolds. Lysate from scaffolds was collected and measured for dsDNA to give an estimation of cell 
number. Groups in the legend marked with (*) are signficantly different from the AS control, the cells from the untreated scaffold 
group. There was so significant difference between time points 14, 21, or 28. Data represent means ± standard deviation (n = 6). 
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Figure 6.2. dsDNA from well remains. Lysate from the wells of scaffolds was collected and measured for dsDNA to give an 
estimation of cell number. Groups in the legend marked with (*) are signficantly different from the AW control, the cells from the 
untreated scaffold group’s well remains. There was no significant difference between time points 14, 21, or 28. Data represent means ± 
standard deviation (n = 6). 
 37 
 
 
 
Figure 6.3. ALP per dsDNA from scaffolds. Lysate from scaffolds was collected and measured for ALP to indicate cell 
differentiation. This number was normalized by dividing by cell number to give ALP produced per cell. Groups in the legend marked 
with (*) are signficantly different from the AS control, the cells from the untreated scaffold group. Only time point pairings 1 versus 7 
and 1 versus 14 were significantly different. Data represent means ± standard deviation (n = 6). 
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Figure 6.4. ALP per dsDNA from well remains. Lysate from the wells of scaffolds was collected and measured for ALP to indicate 
cell differentiation. This number was normalized by dividing by cell number to give ALP produced per cell. Groups in the legend 
marked with (*) are signficantly different from the AW control, the cells from the untreated scaffold group’s well remains. All time 
point pairings were significantly different except day 1 versus 14. Data represent means ± standard deviation (n = 6). 
* 
* 
* 
* 
* 
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Figure 6.5. Total protein per dsDNA from scaffolds. Lysate from scaffolds was collected and measured for total protein to indicate 
cell activity. This number was normalized by dividing by cell number to give total protein produced per cell. Groups in the legend 
marked with (*) are signficantly different from the AS control, the cells from the untreated scaffold group. All time point pairings were 
significantly different. Data represent means ± standard deviation (n = 6). 
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Figure 6.6. Total protein per dsDNA from well remains. Lysate from the wells of scaffolds was collected and measured for total 
protein to indicate cell activity. This number was normalized by dividing by cell number to give total protein produced per cell. 
Groups in the legend marked with (*) are signficantly different from the AW control, the cells from the untreated scaffold group’s well 
remains. All time point pairings were significantly different. Data represent means ± standard deviation (n = 6). 
 
* 
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different from one another. After day 14, the cell count of the well remains also reached a 
plateau, as indicated by the lack of a significant difference between time points 14, 21, 
and 28.  
Next, the ALP per dsDNA plots reveal the alkaline phosphatase produced from 
cells, normalized to cell number. This early stage biomarker of osteoblast activity gives 
an indication of the state of cell differentiation. One to two weeks after preosteoblast cells 
reach confluence, a peak in ALP production occurs that confirms their differentiation 
towards mature osteoblasts. Fig. 6.3 shows a stable amount of ALP produced per cell on 
all scaffold surfaces, with no significant difference between time points except for day 1 
versus 7 and day 1 versus 14. Fig. 6.4 shows the behavior of cells on the tissue culture 
plates with a higher magnitude over time than the cells from scaffolds. There is a 
significant increase in ALP production per cell over time, as only the day 1 versus 14 
pairing showed no significant difference. All the ECM-coated groups well remains 
showed a significant difference in ALP per dsDNA compared to the AW control. On day 
1 for both groups the ALP production appears very high. This is likely a result of the 
normalization calculation of dividing by a low cell count and not a result of high 
osteoblast activity.  
The total protein amount from the micro BCA assay was also normalized to cell 
number. This value gives a measure of cell activity in general. As with the ALP per 
dsdNA plots, the first time point shows artificially high values that are more likely a 
result of low dsDNA values than exceptionally high protein amounts. For the cells from 
scaffolds, Fig. 6.5 showed no significant difference between any groups, though all the 
time points were significantly different from one another. However, no upwards or 
downwards trend in protein production was seen over time. Similarly, Fig. 6.6 displays 
very similar protein per cell counts for all twelve groups for all time points. Here, only a 
significant difference was found between the cell control group C and AW. However, this 
difference is likely another artifact of the high dsDNA count for the C group on day 1. No 
other significant differences between groups was measured. As with the scaffold groups, 
all time points were significantly different from one another though no consistent trend 
could be determined.  
SEM images from the different groups are shown to compare cell deposition on 
the different treated scaffold surfaces over time. A low magnification (50x) and high 
magnification (2,500x) image are shown side-by-side to show the distribution of cell 
deposited matrix across the scaffolds. Each scaffold sample was fixed at the designated 
time point. Samples were gold coated to allow electron microscopy imaging of the non-
conductive samples. In all SEM figures, arrows indicate cell deposits of matrix. Fig. 6.7 
shows the untreated, autoclaved scaffold control group, ‘A.’ On day 1, Fig. 6.7 (a) and 
Fig. 6.7 (b) show no evidence of cell deposition on the control scaffold. On day 14 for 
the control scaffold, Fig. 6.7 (c) shows evidence of matrix deposition across the surface, 
while Fig. 6.7 (d) shows a thin sheet of cell matrix developing across a ceramic pore with 
thin fibers crossing the ceramic surface. On day 28, matrix deposition can still be seen in 
the low magnification image of Fig. 6.7 (e), while a sheet of matrix can be seen across 
the ceramic surface in Fig. 6.7 (f). 
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Figure 6.7. SEM images of control scaffold. Images (a), (c), & (e) were taken at 50x 
magnification. Images (b), (d), & (f) taken at 2,500x. The samples were collected at days 
1 (a), (b); 14 (c), (d); or 28 (e), (f). Arrows indicate cell deposited ECM. 
(a) (b) 
(c) (d) 
(e) (f) 
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Fig. 6.8 shows a similar layout of images from the 14 day medium-soaked 
scaffold group, ‘M14.’ Both Fig. 6.8 (a) and Fig. 6.8 (b) show no signs of cell deposition, 
as would be expected with only one day of exposure to cells. Here, the ceramic surface 
appears smooth in comparison to the untreated scaffold of Fig. 6.7 (a) and Fig. 6.7 (b). 
The exposure to osteogenic medium for 2 weeks allowed the inorganic materials to 
dissolve and precipitate on the surface, creating a smoother scaffold surface compared to 
the autoclaved-only scaffold. Fibers of cell deposited matrix can be seen in Fig. 6.8 (c), 
and a close up of the matrix-surface interaction can be seen in Fig. 6.8 (d). By day 28, 
similar structures of matrix are visible in Fig. 6.8 (e) and Fig. 6.8 (f).  
Lastly, in Fig. 6.9 images from the 14-day cell cultured scaffold group, ‘E14,’ are 
shown at low and high magnifications. Some ECM deposits from the preparation stage 
can be seen on day 1, indicated by arrows in Fig. 6.9 (a). A cell sheet can be seen in the 
upper left and top of the E14 scaffold in Fig. 6.9 (b), indicated by a white arrow. This cell 
matrix was present from the scaffold’s previous 14 day cell culture prior to this 
experiment, as no such observations were made in the control group, A, or medium-
soaked, M14, group. Fig. 6.9 (c) and Fig. 6.9 (d) show the E14 scaffold surface with 
newly developed thin fibers of cell matrix growth across its surface, pointed out by white 
arrows. These thin fibers were not seen on day 1, suggesting that the cells recently 
produced it and that they are not remains from the previous culture period. On day 28, the 
scaffold surface of Fig. 6.9 (e) and Fig. 6.9 (f) also show deposits of ECM, though these 
images can not indicate which of the deposits are from the preparation stage and which 
were newly developed over the 28 day culture period.  
Discussion 
For all groups, SEM images showed a visible amount of cell deposited matrix 
present after 14 days of culture. The medium-soaked groups, regardless of soaking time, 
did not significantly affect the matrix development. The ECM coated scaffolds saw new 
matrix developed on their surface after day 14, but none of the five coated groups 
exhibited any significant effect on the ECM development. 
It was hypothesized that the prelaid ECM coating would enhance cell behavior by 
increasing attachment and speeding the process of differentiation. From the images 
obtained, it appears the cells continued to generate new ECM on the pre-existing ECM, 
much like their behavior on medium-soaked or untreated, autoclaved scaffolds.  
Cell behavior on the treated scaffold groups showed little change compared to the 
cells cultured on untreated scaffolds. From the assays tested, no group stood out as 
having drastically affected preosteoblast behavior. The consistent behavior of the cells for 
all groups suggests that the untreated calcium phosphate material is already very 
biocompatible. Other groups that explored an ECM coating as a means for enhancing cell 
behavior on a material examined metal or polymer surfaces, materials that have no 
biological analogue.3,46 The scaffolds composed of calcium phosphate closely resemble 
hard bone tissue in chemical composition and structure, which contributes to high cell 
attachment and differentiation on the scaffold surface.24 Treatment of the CaP surface  
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Figure 6.8. SEM images of 14-day medium-soaked scaffold. Images (a), (c), & (e) 
were taken at 50x magnification. Images (b), (d), & (f) taken at 2,500x. The samples were 
collected at days 1 (a), (b); 14 (c), (d); or 28 (e), (f). Arrows indicate cell deposited ECM. 
(a) (b) 
(c) (d) 
(e) (f) 
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Figure 6.9. SEM images of 14-day ECM-coated scaffold. Images (a), (c), & (e) were 
taken at 50x magnification. Images (b), (d), & (f) taken at 2,500x. Samples were 
collected at days 1 (a), (b); 14 (c), (d); or 28 (e), (f). Arrows indicate cell deposited ECM. 
(a) (b) 
(c) (d) 
(e) (f) 
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with a cell derived matrix coating or by soaking in medium may not be necessary, or even 
capable of improving scaffold biocompatibility.  
As with the previous chapter, the lack of an ALP peak after cell confluence does 
not allow any statements to be made about the state of cell differentiation in the presence 
of scaffolds. While extracellular matrix can clearly be seen after two weeks, it is possible 
that mineralization of the ECM has not begun by day 28. The plots of ALP per dsDNA 
and total protein per dsDNA do suggest that the measured osteoblasts are active and 
confluent, so further investigation into the state of differentiation of cells on scaffolds is 
necessary. 
Conclusion 
Differences in the surface morphology can be seen between ECM coated, 
medium-soaked, and untreated scaffolds before 14 days of culture. By day 28, no 
distinguishing differences can be seen in the cell matrix coating of any of the eleven 
scaffold groups. There were no measurable changes in preosteoblast cell behavior due to 
the surface treatments as indicated by dsDNA, ALP, and total protein assays. The porous 
β-TCP scaffolds exhibited a high level of biocompatibility with or without any surface 
treatment. A cell derived matrix coating is a viable modification of CaP scaffolds that 
does not negatively impact the performance of the scaffold.  
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CHAPTER 7. DISCUSSION AND CONCLUSIONS 
Overall Findings 
The porous and interconnected beta-tricalcium phosphate scaffolds were 
characterized and found to be similar in composition to the bone tissue they seek to 
replace. Preosteoblast cells seeded on their surface produced a visible amount of 
extracellular matrix after 14 days of culture, and that biological coating can still be seen 
after fairly harsh treatments of decellularization, drying, and sterilization. The cell 
derived matrix persists through a subsequent cell seeding, and can still be seen even after 
another 28 days of culture. From qualitative analysis, more mass of ECM is deposited 
over time on the scaffolds cultured with cells. Also, the surface morphology of the 
medium-soaked scaffolds appeared smoother than the control, likely due to dissolution 
and reprecipitation of the calcium phosphate. 
The biological coating on porous calcium phosphate scaffolds had no significant 
effects on preosteoblasts, according to assays for cell number and an early stage marker 
for osteoblast differentiation, alkaline phosphatase. New ECM was developed even on 
scaffolds with existing ECM. The morphology of the newly developed ECM was similar 
to that generated on both medium-soaked and sterile, untreated scaffolds. The cells 
behaved comparably on ECM coated, medium-soaked, and untreated scaffold surfaces.  
The biocompatibility of the untreated calcium phosphate scaffolds may already be 
sufficient for maximum cell attachment. The high seeding density could also have 
masked any potential benefits of the ECM coating on the scaffolds.  
Conclusions 
It is possible to generate a cell-derived biological polymer coating on the calcium 
phosphate ceramic scaffolds. However there appear to be no beneficial or negative effects 
on cell behavior compared to cells on an untreated scaffold surface. 
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CHAPTER 8. FUTURE DIRECTIONS 
Though benefits to cell attachment and differentiation were not observed with this 
cell derived matrix coating on beta-tricalcium phosphate scaffolds, a biological polymer 
coating can serve other purposes. Bioactive agent delivery is one direction that would be 
very interesting to pursue for this application. Another approach to aid ceramic 
biomaterial research is improving mechanical strength, which may be possible with this 
approach.  
Extracellular matrix naturally retains the activity of bound proteins for local 
cellular use. In fact, the discovery of BMP-2 occurred when the protein was bound to its 
natural carrier, collagen.47 Being able to deliver specific bioactive agents, like the growth 
factor BMP-2, would greatly increase the range of uses this synthetic bone graft material 
has in tissue engineering. For instance, the use of CaP scaffolds to enhance regeneration 
of vessels alongside bone growth has been examined by some groups.53 Delivering 
bioactive agents known to promote neovascularization could improve the overall quality 
of tissue developed on the ceramic scaffold. 
Though not examined in this experiment, mechanical stability provided by a 
pervasive polymer coating is a potential area of interest. Bone tissue itself derives many 
of its unique properties through this composition of materials. A thorough study on 
mechanical strength in compressive and shear forces may reveal an additional benefit to 
this cell derived matrix coating. 
Most importantly, the use of the matrix for osteogenic factor retention should be 
examined. Either by immunostaining, ELISA, or more cell behavior assays, the ability of 
the decellularized and sterilized ECM to provide a structural support for bioactive agents 
should be examined. Without this ability, the ECM coating offers little benefits to the 
already biocompatible surface of these porous calcium phosphate scaffolds. 
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